Nuotai Biotech’s Lianyungang plant has passed a GMP compliance inspection for
its small‑volume injection (non‑terminally sterilized cartridge) production line
and received a compliance notice from the Jiangsu Provincial Medical Products
Administration. The line is designed for 200 mln units/year, supports
high‑speed, large‑volume, multi‑product runs including suspension processes, and
allows flexible expansion, adding contract‑manufacturing capacity for
injectables, cartridges and injection-pen platforms.
